Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 70

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 70
---
 The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

Research and Development Cost

Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company’s internally funded development of the Company’s product developments and patents. The Company R&D costs were $0 and $32,500 for the quarters ended June 30, 2025 and 2024.

<div align='center'>53</div>

Fair Value Measurement

The estimated fair values of financial instruments reported in the consolidated financial statements have been determined using available market information and valuation methodologies, as applicable. The fair value of cash due to its short maturity is classified as a Level 1 instrument within the fair value hierarchy.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Entities are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value based upon the following fair value hierarchy:

| Level 1 — | Quoted prices in active                                                                                                                   
 markets for identical assets or liabilities;                                                                                              |
| Level 2 — | Observable inputs other                                                                                                                   
 than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other      
 inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; 
 and                                                                                                                                       |
| Level 3 — | Unobservable inputs that                                                                                                                  
 are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.                    |

As of June 30, 2025, the following table represents the Company’s fair value hierarchy for items that are required to be measured at fair value on a recurring basis:

|                            |     | Level 
 1     |     | Level 
 2     |